Current Trends in Monoclonal Antibody Development and Manufacturing

Edited by

Steven J. Shire
Genentech, Inc.,
San Francisco, CA
USA

Wayne Gombotz
Omeros Corporation
Seattle, WA
USA

Karoline Bechtold-Peters
Boehringer Ingelheim
Pharma, Biberach
Germany

James Andya
Genentech, Inc.,
San Francisco, CA
USA

Contents

1 Introduction 1
Wayne R. Gombotz and Steven J. Shire

Part I Design Of Therapeutic MABS

2 CDR Repair: A Novel Approach to Antibody Humanization 9
Mark S. Dennis

3 Nanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies 29
Gholamreza Hassanzadeh Ghassabeh, Serge Muyldermans, and Dirk Saerens

Part II Expression and Production of MABS

4 GPEx® A Flexible Method for the Rapid Generation of Stable, High Expressing, Antibody Producing Mammalian Cell Lines 51
Gregory T. Bleck

5 Advancing Our Cell Culture Platform: Incorporating Lessons Learned and New Technologies 63
Carole Heath

Part III Recovery and Purification

6. Addressing Changes Associated with Technology Transfer: A Case Study 75
Michele M. Myers, Camille Keating, Joann Bannon, Donald S. Neblock, and Peter W. Wojciechowski

7 Concepts for Disposables in Biopharmaceutical Manufacture 87
Joachim K. Walter and Uwe Gottschalk

Part IV Formulation and Delivery

8 Formulation and Delivery Issues for Monoclonal Antibody Therapeutics 103
Ann L. Daugherty and Randall J. Mrsny

9 Challenges in the Development of High Protein Concentration Formulations 131
Steven J. Shire, Zahra Shahrokh, and Jun Liu

10 Protein Immobilization by Crystallization and Precipitation: An Alternative to Lyophilization 149
Karoline Bechtold-Peters

Part V Analytics and Specification Setting for MABS

11 Characterizing High Affinity Antigen/Antibody Complexes by Kinetic and Equilibrium Based Methods 179
Andrew W. Drake, David G. Myszka, and Scott L. Klakamp

12 Analytical Characterization of Monoclonal Antibodies: Linking Structure to Function 193
Reed J. Harris, Edward T. Chin, Frank Macchi, Rodney G. Keck, Bao-Jen Shyong, Victor T. Ling, Armando J. Cordoba, Melinda Marian, Don Sinclair, John E. Battersby, and Andy J.S. Jones

13 Analysis of Irreversible Aggregation, Reversible Self-association and Fragmentation of Monoclonal Antibodies by Analytical Ultracentrifugation 207
James D. Andya, Jun Liu, and Steven J. Shire

14 Biophysical Signatures of Monoclonal Antibodies 229
N. Harn, T. Spitznagel, M. Perkins, C. Allan, S. Shire, and C. R. Middaugh

Part VI Pharmacokinetics and Immunogenicity

15 Impact of Fc Glycosylation on Monoclonal Antibody Effector Functions and Degradation by Proteases 249
T. Shantha Raju

16 Immunogenicity Assessment of Antibody Therapeutics 271
P. Stas, Y. Gansemans, and I. Lasters

Part VII Armed Antibodies and New Classes of Antibodies

17 Production of Monoclonal Antibodies in *E. coli* 295
Dorothea E. Reilly and Daniel G. Yansura

18 Recent Advancements in the Use of Antibody Drug Conjugates for Cancer Therapy 309
Peter D. Senter

19 Antibody Radiolabeling 323
Corinne Bensimon and Russell Redshaw

Index 345